Biogen Inc. $BIIB Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB decreased its holdings in Biogen Inc. (NASDAQ:BIIB) by 15.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 84,228 shares of the biotechnology company’s stock after selling 15,088 shares during the quarter. Handelsbanken Fonder AB’s holdings in Biogen were worth $14,823,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. Advisory Services Network LLC grew its position in Biogen by 3.9% in the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after buying an additional 68 shares during the last quarter. CVA Family Office LLC grew its position in Biogen by 18.1% in the third quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock worth $65,000 after buying an additional 71 shares during the last quarter. Davis Investment Partners LLC grew its position in Biogen by 1.7% in the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock worth $778,000 after buying an additional 71 shares during the last quarter. Optas LLC grew its position in Biogen by 4.5% in the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock worth $300,000 after buying an additional 73 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its position in Biogen by 8.1% in the third quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock worth $167,000 after buying an additional 89 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Freedom Capital upgraded shares of Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Mizuho lifted their price target on shares of Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Wedbush lifted their price target on shares of Biogen from $191.00 to $196.00 and gave the stock a “neutral” rating in a research report on Thursday, April 30th. Weiss Ratings upgraded shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 1st. Finally, Wells Fargo & Company raised their price objective on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Sunday, February 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Biogen presently has an average rating of “Moderate Buy” and a consensus price target of $215.62.

Biogen Trading Up 0.9%

Biogen stock opened at $189.47 on Friday. The company has a 50 day moving average price of $185.42 and a 200 day moving average price of $180.66. Biogen Inc. has a 52 week low of $121.05 and a 52 week high of $205.97. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06. The firm has a market capitalization of $27.97 billion, a price-to-earnings ratio of 20.33, a P/E/G ratio of 1.66 and a beta of 0.19.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same quarter last year, the business posted $3.02 EPS. The company’s revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Research analysts forecast that Biogen Inc. will post 14.18 EPS for the current year.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.